array:24 [
  "pii" => "S2173574324000212"
  "issn" => "21735743"
  "doi" => "10.1016/j.reumae.2023.07.006"
  "estado" => "S300"
  "fechaPublicacion" => "2024-02-01"
  "aid" => "1709"
  "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
  "copyrightAnyo" => "2023"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Reumatol Clin. 2024;20:113"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S1699258X23001778"
      "issn" => "1699258X"
      "doi" => "10.1016/j.reuma.2023.07.005"
      "estado" => "S300"
      "fechaPublicacion" => "2024-02-01"
      "aid" => "1709"
      "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "cor"
      "cita" => "Reumatol Clin. 2024;20:113"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>"
        "titulo" => "Comentarios sobre el tratamiento de la osteoporosis por corticoides"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:1 [
            "paginaInicial" => "113"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Comments about treatment of glucocorticoid-induced osteoporosis"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Osvaldo Daniel Messina"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Osvaldo Daniel"
                "apellidos" => "Messina"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2173574324000212"
          "doi" => "10.1016/j.reumae.2023.07.006"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000212?idApp=UINPBA00004M"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23001778?idApp=UINPBA00004M"
      "url" => "/1699258X/0000002000000002/v1_202401170557/S1699258X23001778/v1_202401170557/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2173574324000066"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2023.09.005"
    "estado" => "S300"
    "fechaPublicacion" => "2024-02-01"
    "aid" => "1724"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Reumatol Clin. 2024;20:114-5"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Response to Letter to the Editor&#58; Thresholds based on bone mineral density for therapeutic decision-making in postmenopausal women and men older than 50 years old under glucocorticoid therapy"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "114"
          "paginaFinal" => "115"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Respuesta carta al editor&#58; Umbrales densitom&#233;tricos de densidad mineral &#243;sea para considerar tratamiento en pacientes mujeres postmenop&#225;usicas y hombres mayores de 50 a&#241;os en tratamiento con glucocorticoides"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Mar&#237;a Lorena Brance, Mar&#237;a Silvia Larroud&#233;, Luis Fernando Somma, Luis Agust&#237;n Ramirez Stieben, Lucas R&#46; Brun"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Mar&#237;a Lorena"
              "apellidos" => "Brance"
            ]
            1 => array:2 [
              "nombre" => "Mar&#237;a Silvia"
              "apellidos" => "Larroud&#233;"
            ]
            2 => array:2 [
              "nombre" => "Luis Fernando"
              "apellidos" => "Somma"
            ]
            3 => array:2 [
              "nombre" => "Luis Agust&#237;n"
              "apellidos" => "Ramirez Stieben"
            ]
            4 => array:2 [
              "nombre" => "Lucas R&#46;"
              "apellidos" => "Brun"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1699258X23002024"
        "doi" => "10.1016/j.reuma.2023.09.008"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X23002024?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000066?idApp=UINPBA00004M"
    "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000066/v1_202402220812/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2173574324000108"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2024.01.003"
    "estado" => "S300"
    "fechaPublicacion" => "2024-02-01"
    "aid" => "1727"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Reumatol Clin. 2024;20:108-12"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>"
      "titulo" => "Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "108"
          "paginaFinal" => "112"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Efecto del tratamiento combinado con prednisona y metotrexato versus prednisona sola sobre los par&#225;metros de laboratorio en arteritis de c&#233;lulas gigantes"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Fig&#46; 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1592
              "Ancho" => 1671
              "Tamanyo" => 115163
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Relationship between ESR and prednisone dose in each group&#46; The gray line and gray rhombs indicate the mean ESR and median prednisone dose respectively in every time point for the patients treated with methotrexate and prednisone&#46; The black line and black rectangles indicate the mean ESR and median prednisone dose in every time point for patients treated with prednisone alone&#46; Arrows indicate the time at which relapses occurred in both groups&#46; As you can see&#44; relapses were more frequent in the first year of treatment in both groups and were accompanied by a significant rise in the mean ESR value&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ines Perez-Sancristobal, Paula Alvarez-Hernandez, Cristina Lajas-Petisco, Benjamin Fernandez-Gutierrez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Ines"
              "apellidos" => "Perez-Sancristobal"
            ]
            1 => array:2 [
              "nombre" => "Paula"
              "apellidos" => "Alvarez-Hernandez"
            ]
            2 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Lajas-Petisco"
            ]
            3 => array:2 [
              "nombre" => "Benjamin"
              "apellidos" => "Fernandez-Gutierrez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000108?idApp=UINPBA00004M"
    "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000108/v1_202402220812/en/main.assets"
  ]
  "en" => array:12 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Comments about treatment of glucocorticoid-induced osteoporosis"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#44;"
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "113"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Osvaldo Daniel Messina"
        "autores" => array:1 [
          0 => array:4 [
            "nombre" => "Osvaldo Daniel"
            "apellidos" => "Messina"
            "email" => array:1 [
              0 => "drosvaldodanielmessina@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "IRO Centro M&#233;dico&#44; Buenos Aires&#44; Argentina"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Comentarios sobre el tratamiento de la osteoporosis por corticoides"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The reason for this letter is a number of comments related to the article on treatment thresholds in patients over 50&#8239;years of age by Brance et al&#46;&#44; published in CLINICAL RHEUMATOLOGY in October 2022&#44; which demonstrated multiple misconceptions regarding glucocorticoid-induced osteoporosis&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">In our opinion&#44; the most important of these are as follows&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1</span><p id="par0015" class="elsevierStylePara elsevierViewall">It is totally incorrect to set a threshold for treatment intervention based almost exclusively upon an arbitrary densitometric value&#44; since glucocorticoids produce changes in bone structure in three dimensions&#44; which cannot be measured with DXA as it is a planar method&#46;</p></li></ul></p><p id="par0020" class="elsevierStylePara elsevierViewall">For this reason&#44; at the same T-score value&#44; the fracture rate in patients with corticoid-induced osteoporosis is twice that of patients with primary osteoporosis&#46; Consequently&#44; there are fractured patients with higher and even normal bone mineral density values vs&#46; patients with primary osteoporosis&#46; For this reason&#44; basing treatment thresholds on bone mineral density values is a serious error which&#44; in addition&#44; shows ignorance of the biomechanical effects of corticosteroids on bone&#46;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2</span><p id="par0025" class="elsevierStylePara elsevierViewall">It is absolutely mandatory to incorporate FRAX&#44; depending on the dose of corticosteroids used&#44; since many other factors influence the risk of fracture&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3</span><p id="par0030" class="elsevierStylePara elsevierViewall">It is necessary to divide patients into those over and under 40&#8239;years of age&#46; Patients under 40&#8239;years of age&#44; for whom T-score values should not be used&#44; cannot be disregarded&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4</span><p id="par0035" class="elsevierStylePara elsevierViewall">No modern clinical practice guidelines consider almost exclusively&#44; as this article does&#44; the T-score value &#40;ACR 2017 guidelines updated in 2022&#44; Latin American clinical practice guidelines from the International Osteoporosis Foundation &#91;IOF&#93; 2022 and the Brazilian <span class="elsevierStyleItalic">Guidas de Pr&#225;ctica Cl&#237;nica 2020&#44;</span> which are the most representative regional guidelines and were not referenced in this article&#41;&#46;</p></li></ul></p><p id="par0040" class="elsevierStylePara elsevierViewall">We consider that this article leads to erroneous clinical and treatment behaviours&#44; as it is incomplete in terms of treatment guidance in the management of patients treated with glucocorticoids&#46; We suggest reading the recently published modern guidelines cited above&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#8211;5</span></a></p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evidence based Latin American Guuidelines of Clinical practice on prevention&#44; diagnosis&#44; management and treatment of glucocorticoid induced osteoporosis&#46; A 2022 update&#58; This manuscript has been produced under the auspices of the Committee of National Societies &#40;CNS&#41; and the Committee of Scientific Advisors &#40;CSA&#41; of the International Osteoporosis Foundation&#44; Geneva&#44; Switzerland"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "O&#46;D&#46; Messina"
                            1 => "M&#46; Vidal Wilman"
                            2 => "J&#46;A&#46; Morales Torres"
                            3 => "L&#46;F&#46; Vidal Neira"
                            4 => "C&#46;B&#46; Arguissain"
                            5 => "R&#46;M&#46; Pereira"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40520-022-02261-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aging Clin Exp Res"
                        "fecha" => "2022"
                        "volumen" => "34"
                        "paginaInicial" => "2591"
                        "paginaFinal" => "2602"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36348222"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of glucocorticoid induced osteoporosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "O&#46;D&#46; Messina"
                            1 => "L&#46;F&#46; Vidal Neira"
                            2 => "M&#46; Vidal Wilman"
                            3 => "I&#46;E&#46;M&#46; Bultink"
                            4 => "H&#46; Raterman"
                            5 => "W&#46; Lems"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40520-021-01823-0"
                      "Revista" => array:7 [
                        "tituloSerie" => "Aging Clin Exp Res"
                        "fecha" => "2021"
                        "volumen" => "33"
                        "numero" => "4"
                        "paginaInicial" => "793"
                        "paginaFinal" => "804"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33751462"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines for the prevention and treatment of glucocorticoid &#8211; induced osteoporosis&#58; an update of Brazilian Society of Rheumatology &#40; 2020&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Pereira"
                            1 => "M&#46;O&#46; Perez"
                            2 => "A&#46;P&#46; Paula"
                            3 => "C&#46; Moreira"
                            4 => "C&#46; Castro"
                            5 => "C&#46; Zerbini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11657-021-00902-z"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arch Osteoporos"
                        "fecha" => "2021"
                        "volumen" => "16"
                        "paginaInicial" => "49"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33646403"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced Osteoporosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Buckley"
                            1 => "G&#46; Guyatt"
                            2 => "H&#46; Fink"
                            3 => "M&#46; Cannon"
                            4 => "J&#46; Grossman"
                            5 => "K&#46;E&#46; Hansen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.40137"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheumatol"
                        "fecha" => "2017"
                        "volumen" => "69"
                        "paginaInicial" => "1521"
                        "paginaFinal" => "1537"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28585373"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2022 American College of Rheumatology guideline for the prevention and reatment of glucocorticoid &#8211; induced osteoporosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Humphreys"
                            1 => "L&#46; Russell"
                            2 => "M&#46;I&#46; Danila"
                            3 => "H&#46;A&#46; Fink"
                            4 => "G&#46; Guyatt"
                            5 => "M&#46; Cannon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.42646"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheumatol"
                        "fecha" => "2023"
                        "volumen" => "75"
                        "paginaInicial" => "2088"
                        "paginaFinal" => "2102"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37845798"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735743/0000002000000002/v1_202402220812/S2173574324000212/v1_202402220812/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "8400"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735743/0000002000000002/v1_202402220812/S2173574324000212/v1_202402220812/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324000212?idApp=UINPBA00004M"
]
Share
Journal Information
Vol. 20. Issue 2.
Pages 113 (February 2024)
Vol. 20. Issue 2.
Pages 113 (February 2024)
Letter to the Editor
Full text access
Comments about treatment of glucocorticoid-induced osteoporosis
Comentarios sobre el tratamiento de la osteoporosis por corticoides
Visits
245
Osvaldo Daniel Messina
Corresponding author
IRO Centro Médico, Buenos Aires, Argentina
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

The reason for this letter is a number of comments related to the article on treatment thresholds in patients over 50 years of age by Brance et al., published in CLINICAL RHEUMATOLOGY in October 2022, which demonstrated multiple misconceptions regarding glucocorticoid-induced osteoporosis.

In our opinion, the most important of these are as follows:

  • 1

    It is totally incorrect to set a threshold for treatment intervention based almost exclusively upon an arbitrary densitometric value, since glucocorticoids produce changes in bone structure in three dimensions, which cannot be measured with DXA as it is a planar method.

For this reason, at the same T-score value, the fracture rate in patients with corticoid-induced osteoporosis is twice that of patients with primary osteoporosis. Consequently, there are fractured patients with higher and even normal bone mineral density values vs. patients with primary osteoporosis. For this reason, basing treatment thresholds on bone mineral density values is a serious error which, in addition, shows ignorance of the biomechanical effects of corticosteroids on bone.

  • 2

    It is absolutely mandatory to incorporate FRAX, depending on the dose of corticosteroids used, since many other factors influence the risk of fracture.

  • 3

    It is necessary to divide patients into those over and under 40 years of age. Patients under 40 years of age, for whom T-score values should not be used, cannot be disregarded.

  • 4

    No modern clinical practice guidelines consider almost exclusively, as this article does, the T-score value (ACR 2017 guidelines updated in 2022, Latin American clinical practice guidelines from the International Osteoporosis Foundation [IOF] 2022 and the Brazilian Guidas de Práctica Clínica 2020, which are the most representative regional guidelines and were not referenced in this article).

We consider that this article leads to erroneous clinical and treatment behaviours, as it is incomplete in terms of treatment guidance in the management of patients treated with glucocorticoids. We suggest reading the recently published modern guidelines cited above.1–5

References
[1]
O.D. Messina, M. Vidal Wilman, J.A. Morales Torres, L.F. Vidal Neira, C.B. Arguissain, R.M. Pereira, et al.
Evidence based Latin American Guuidelines of Clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation, Geneva, Switzerland.
Aging Clin Exp Res, 34 (2022), pp. 2591-2602
[2]
O.D. Messina, L.F. Vidal Neira, M. Vidal Wilman, I.E.M. Bultink, H. Raterman, W. Lems.
Management of glucocorticoid induced osteoporosis.
Aging Clin Exp Res, 33 (2021), pp. 793-804
[3]
R.M. Pereira, M.O. Perez, A.P. Paula, C. Moreira, C. Castro, C. Zerbini, et al.
Guidelines for the prevention and treatment of glucocorticoid – induced osteoporosis: an update of Brazilian Society of Rheumatology ( 2020).
Arch Osteoporos, 16 (2021), pp. 49
[4]
L. Buckley, G. Guyatt, H. Fink, M. Cannon, J. Grossman, K.E. Hansen, et al.
2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced Osteoporosis.
Arthritis Rheumatol, 69 (2017), pp. 1521-1537
[5]
L. Humphreys, L. Russell, M.I. Danila, H.A. Fink, G. Guyatt, M. Cannon, et al.
2022 American College of Rheumatology guideline for the prevention and reatment of glucocorticoid – induced osteoporosis.
Arthritis Rheumatol, 75 (2023), pp. 2088-2102
Copyright © 2023. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?